Warning letterPosted April 7, 2026
FDA warning letter to Lovega LLC dba Pink Pony Peptides
Unapproved New Drugs Sold Over the Internet
FDA posted a warning letter to Lovega LLC dba Pink Pony Peptides on April 7, 2026; the letter is dated March 31, 2026. Subject: Unapproved New Drugs Sold Over the Internet. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- Lovega LLC dba Pink Pony Peptides
- Subject
- Unapproved New Drugs Sold Over the Internet
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-03-31
- Posted by FDA
- 2026-04-07
- Source
- FDA warning letters ↗
CFR cited
The record cites 1 section of 21 CFR Part 201.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch Lovega LLC dba Pink Pony Peptides
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Lovega LLC dba Pink Pony Peptides.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.